Adiponectin

Adiponectin is an adipocyte-derived hormone that circulates at high concentrations (approximately 3-6 orders of magnitude greater than typical hormones) and serves as a key regulator of glucose and lipid metabolism. PMID 29978896PMID 31731079 It is secreted primarily by white adipose tissue, though cardiomyocytes, endothelial cells, and skeletal muscle cells also produce it. PMID 35890325

Biological functions include enhancing insulin sensitivity by stimulating fatty acid oxidation in skeletal muscle and suppressing hepatic glucose production. PMID 29978896PMID 26993047 Adiponectin activates AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPARα) pathways through its receptors AdipoR1 and AdipoR2. PMID 29978896 Beyond metabolic effects, adiponectin exhibits anti-inflammatory, anti-apoptotic, and cardioprotective properties by reducing vascular inflammation, inhibiting endothelial adhesion molecule expression, and decreasing oxidative stress. PMID 29978896PMID 22796520 Uniquely among adipokines, circulating adiponectin levels are inversely correlated with body fat mass despite being produced by adipocytes. PMID 31731079PMID 35196429

Adiponectin is considered an exerkine. Exercise increases adiponectin levels in rodents, enhancing fatty acid oxidation and glucose uptake in skeletal muscle. PMID 40157803 In humans, chronic exercise training increases adiponectin receptor expression, which may mediate improvements in insulin resistance following exercise. PMID 25126860 Adiponectin crosses the blood-brain barrier where it modulates hippocampal neurogenesis, mood regulation, and stimulates anti-inflammatory cytokine release. PMID 40157803 These exercise-responsive properties—increased secretion with physical activity, systemic circulation to distant tissues, and beneficial metabolic effects—support its classification as an exerkine, though it functions as an adipokine under baseline conditions. PMID 40157803PMID 22876920

Human studies show that exercise interventions can modulate circulating adiponectin levels, particularly when combined with dietary modifications. PMID 22876920

Adiponectin represents a therapeutic target for metabolic and cardiovascular diseases based on its insulin-sensitizing, anti-inflammatory, and cardioprotective properties. PMID 23448486PMID 24957699 Therapeutic strategies include direct replacement and indirect upregulation approaches, though clinical translation remains limited. PMID 25818192

Direct approaches include recombinant adiponectin administration, gene transfer, synthetic peptide mimetics, and adiponectin receptor agonists (e.g., AdipoRon). PMID 23448486PMID 22876919PMID 25818192 Receptor agonists bypass the need for full-length protein and demonstrate favorable effects in preclinical HFpEF models. PMID 22876919PMID 40886173 However, complex oligomeric structure, short half-life, and delivery challenges limit protein-based approaches. PMID 25818192PMID 22876919

Indirect pharmacological strategies to increase endogenous adiponectin include thiazolidinediones (PPARγ agonists), which exert insulin-sensitizing effects predominantly through adiponectin upregulation, though cardiovascular and bone safety concerns limit use. PMID 34181914PMID 25818192PMID 12611609 Fibric acid derivatives, RAAS blockers, and certain statins show modest adiponectin-elevating effects. PMID 24957699PMID 25818192PMID 24603219

Lifestyle interventions including weight loss, Mediterranean diet, omega-3 supplementation, and regular exercise reliably modulate adiponectin levels or receptor expression. PMID 26764331PMID 24603219PMID 22257055

Despite compelling preclinical evidence demonstrating metabolic correction and cardioprotection in animal models, PMID 23448486PMID 40886173PMID 19906806 no adiponectin-based therapeutic has achieved regulatory approval. Thiazolidinediones and lifestyle modifications remain the only evidence-based approaches to therapeutically modulate the adiponectin system in humans. PMID 25818192